Key result
High admission serum endocan predicts in-hospital MACE in ACS patients.
Why the study?
The study evaluated the prognostic value of serum endocan levels in patients with ACS through correlation with the TIMI risk score and clinical outcomes.
Does serum endocan level predict major adverse cardiovascular events in patients with acute coronary syndrome?
Cross-Sectional (n=320)
Does serum endocan level predict major adverse cardiovascular events in patients with acute coronary syndrome?
High endocan levels on admission independently predict worse cardiovascular outcomes and correlate with higher TIMI risk scores in patients with ACS.
Endocan may aid ACS risk stratification; hypothesis-generating and requires prospective validation before clinical adoption.
We assessed the prognostic value of serum levels of endocan in patients with the acute coronary syndrome (ACS) through its correlation with the Thrombolysis in Myocardial Infarction (TIMI) risk score and compared the possible association with clinical outcomes. In this prospective cross-sectional study, we enrolled 320 patients with documented ST-segment elevation myocardial infarction (STEMI), non-STEMI (NSTEMI), or unstable angina (UA) who underwent diagnostic coronary angiography. Endocan was measured soon after admission in the emergency department. In-hospital death, heart failure, and recurrent infarction were considered major adverse cardiac events (MACEs). There was a significant positive correlation between endocan level and TIMI risk score and MACE. The optimal cutoff values of endocan to predict clinical end points were 3.45 ng/mL in patients with STEMI and 2.85 ng/mL in patients with UA/NSTEMI. Multivariate logistic regression analysis indicated that endocan independently correlated with MACE. Moreover, cardiac troponin I, creatine kinase-MB, and circulating endocan were found to be independently associated with MACE in patients with ACS. In conclusion, a high endocan level on hospital admission is an independent predictor of worse cardiovascular outcomes and higher TIMI risk score in patients with ACS.
No takes yet. Share an insight, caveat, or question.
Ziaee et al. (2018) conducted a cross-sectional in Acute coronary syndrome (n=320). Serum endocan levels was evaluated on Major adverse cardiac events (in-hospital death, heart failure, and recurrent infarction). High serum endocan levels on admission independently predicted major adverse cardiac events in ACS patients, with optimal cutoffs of 3.45 ng/mL for STEMI and 2.85 ng/mL for UA/NSTEMI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: